Диабетическая нефропатия. Зависит ли ренопротекция от выбора сахароснижающей терапии?

Начало XXI в. в диабетологии характеризуется серьезным прорывом в разработке новых фармакологических агентов и изменением подходов к лечению сахарного диабета 2-го типа. Изменение концепции подхода к лечению с глюкоцентрической на многофакторную и создание новых групп противо-диабетических препаратов с множественными негликемическими эффектами существенно усложнило для практикующих врачей выбор терапии для каждого конкретного больного, но в то же время позволило сделать его максимально оптимальным. Это, несомненно, требует расширения знаний специалистов о негликемических эффектах противодиабетических лекарственных средств. Настоящий обзор посвящен одному из таких эффектов - ренопротективным влияниям различных групп сахароснижаю-щих препаратов, с акцентом на новые группы, вошедшие в российские алгоритмы за последнее десятилетие (агонисты рецепторов ГПП-1, ингибиторы ДПП-4, ингибиторы натрий-глюкозного ко-транспортера 2-го типа). Он может быть полезен как исследователям, так и практикующим врачам, старающимся на современном уровне выбирать оптимальную терапию для своих пациентов.

диабетическая нефропатия, ренопротекция, противодиабетические препараты, артериальное давление, метформин, препараты сульфонилмочевины, тиазолидиндионы, ингибиторы, дипептидилпептидазы-4, агонисты рецепторов глюкагоноподобного пептида-1

1. TriggLe CR, Ding H. Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chronic Dis. 2014, 5(6): 245-268

2. PLantinga LC, Crews DC, Coresh J, et aL. Prevalence of chronic kidney disease in US aduLts with undiagnosed diabetes or prediabe-tes. Clin J Am Soc Nephrol. 2010, 5(4):673-682.

3. Шестакова М.В., Шамхалова М.Ш., Ярек-Мартынова И.Я. и соавт. Федеральные клинические рекомендации по диагностике, скринингу, профилактике и лечению хронической болезни почек у больных сахарным диабетом. М., 2014. 39 c.

4. KDOOI clinical practice guideline for diabetes and CKD: 2012 update. Am J of Kidn Dis, 2012, 60(5): 850-886.

5. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes meLLitus. Mayo Clin Proc, 2011, 86(5): 444-456.

6. Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoaLbuminuric type 1 diabetic patients: an indicator of more advanced glomerular Lesions. Diabetes, 2003, 52: 1036-1040.

7. Kramer CK, Leitao CB, Pinto LC, et aL. CLinicaL and Laboratory profiLe of patients with type 2 diabetes with Low gLomeruLar fiLtration rate and normoaLbuminuria. 2007, 30(8):1998-2000.

8. Kramer HJ, Nguyen OD, Curhan G, Hsu CY. RenaL insufficiency in the absence of aLbuminuria and retinopathy among aduLts with type 2 diabetes meLLitus. JAMA, 2003, 289: 3273-3277.

9. HoLman RR, PauL SK, BetheL MA, et aL. 10-year foLLow-up of intensive gLucose controL in type 2 diabetes. N Engl J Med, 2008, 359(15): 15771589.

10. Zhang OL, Rothenbacher D. PrevaLence of chronic kidney disease in popuLation-based studies: systematic review, 2008, 11(8):117. doi: 10.1186/1471-2458-8-117.

11. BadaL SS, Danesh FR. New insights into moLecuLar mechanisms of diabetic kidney disease. Am J Kidney Dis, 2014, 63: S63-83.

12. SatcheLL SC, Tooke JE. What is the mechanism of microaLbuminuria in diabetes: a roLe for the gLomeruLar endotheLium? Diabetologia, 2008, 51(5): 714-725.

13. Iwasaki H, Okamoto R, Kato S. High gLucose induces pLasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-kB activation in bovine aortic endotheLiaL ceLLs. AtheroscLerosis, 2008, 196 (1): 22-28.

14. Bottinger EP , Bitzer M. TGF-p signaLing in renaL disease. CLin J Am Soc NephroL, 2002, 13(10): 2600-2610.

15. G^de P, VedeL P, Larsen N, et aL. MuLtifactoriaL intervention and cardiovascuLar disease in patients with type 2 diabetes. N EngL J Med, 2003, 348 (5): 383-393.

16. Lacquaniti A, BoLignano D, Donato V, et aL. ALterations of Lipid metaboLism in chronic nephropathies: mechanisms, diagnosis and treatment. Kidney BLood Press Res, 2010, 33(2):100-110.

17. Ozsoy RC, van der Steeg WA, KasteLein JJ, et aL. DysLipidaemia as predictor of progressive renaL faiLure and the impact of treatment with atorv-astatin. NephroL DiaL TranspLant, 2007, 22(6):1578-1586.

18. Gouva C, NikoLopouLos P, loannidis JP, Siamopou-Los KC. Treating anemia earLy in renaL faiLure patients sLows the decLine of renaL function: a randomized controLLed triaL. Kidney Int, 2004, 66(2): 753-760

19. CignareLLi M, Lamacchia O, Di PaoLo S, GesuaLdo L. Cigarette smoking and kidney dysfunction in diabetes meLLitus. J NephroL, 2008, 21(2)180-189.

20. Ting SM, Nair H, Ching I, et aL. Overweight, obesity and chronic kidney disease. Nephron CLin Pract, 2009, 112(3):121-127.

21. Eknoyan G. Obesity, diabetes, and chronic kidney disease. Curr Diab Rep, 2007, 7(6): 449-453.

22. Afshinnia F, WiLt TJ, DuvaL S, et aL. Weight Loss and proteinuria: systematic review of cLinicaL triaLs and comparative cohorts. NephroL DiaL TranspLant, 2010, 25(4):1173-1183.

23. Cherney DZ, Perkins BA, SoLeymanLou N, et aL. RenaL hemodynamic effect of sodium-gLucose cotransporter 2 inhibition in patients with type 1 diabetes meLLitus. CircuLation, 2014, 5(129): 587-597.

24. Sasson AN, Cherney DZ. RenaL hyperfiLtration reLated to diabetes meLLitus and obesity in human disease. WorLd J Diabetes, 2012, 3: 1-6.

25. Andrianesis V, Doupis J. The roLe of kidney in gLucose homeostasis - SGLT2 inhibitors, a new approach in diabetes treatment. Expert Rev CLin PharmacoL, 2013, 6(5): 519-539.

26. HaLuzik M, FroLik J, RychLik I. RenaL effects of DPP-4 inhibitors: a focus on microaLbuminuria. Int J EndocrinoL, 2013, 2013: 895102. doi:10.1155/2013/895102.

27. AACE/ACE CLinicaL practice guideLines for deveLoping a diabetes meLLitus comprehensive care pLan. Endocr Pract, 2015, 21(S. 1): 438-447,

28. Vasisht KP, Chen S-C, Peng Y, Bakris GL. Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab, 2010, 12 (12): 1079-1083.

29. NoveL assay of metformin LeveLs in patients with type 2 diabetes and varying LeveLs of renaL function. CLinicaL recommendations. Diabetes Care, 2010, 33(6): 1291-1293.

30. Herrington WG, Levy JB. Metformin: effective and safe in renaL disease? Int UroL NephroL, 2008, 40:411-417.

31. Inzucchi SE, Lipska KJ, Mayo H, et aL. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA, 2014, 312(24): 2668-75.

32. Owen MR, Doran E, HaLestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of compLex 1 of the mito-chondriaL respiratory chain. Biochem J, 2000, 348: 607-614.

33. Gundewar S. Activation of AMP-activated protein kinase by metformin improves Left ventricuLar function and survivaL in heart faiLure. Circ Res, 2009, 104: 403-411.

34. Russell RR, Li J, Coven DL, et aL. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J CLin Invest, 2004,114: 495-503.

35. Takiyama Y, Harumi T, Watanabe J, et aL. TubuLar injury in a rat modeL of type 2 diabetes is prevented by metformin: a possibLe roLe of HIF-1a expression and oxygen metaboLism. Diabetes. 2011, 60(3):981-992.

36. Seo-Mayer PW, ThuLin G, Zhang L, et aL. Preactivation of AMPK by metformin may ameLiorate the epitheLiaL ceLL damage caused by renaL ischemia. Am J PhysioL RenaL PhysioL. 2011, 301(6):1346-1357.

37. Nowak G, Bakajsova D, SamareL AM. Protein kinase C-epsiLon activation induces mitochon-driaL dysfunction and fragmentation in renaL proximaL tubuLes. Am J PhysioL RenaL PhysioL, 2011, 301(1):197-208.

38. DetaiLLe D, Guigas B, Chauvin C, et aL. Metformin prevents high-gLucose-induced endotheLiaL ceLL death through a mitochondriaL permeabiLity transition-dependent process. Diabetes, 2005, 21(7):2179-2187.

39. Nasri RH. Renoprotective effects of metformin Daru. 2013; 21(1): 36.

40. Bayrasheva V, Grineva E, Babenko A, et aL. Metformin restores tubuLar, but not gLomeruLar, injury in type 2 diabetic rats. Diabetes TechnoL The, 2015, 17(S1)A477.

41. WuLffeLe MG, Kooy A, De Zeeuw D, et aL. The effect of metformin on bLood pressure, pLasma choLesteroL and trigLycerides in type 2 diabetes meLLitus: a systematic review. J Int Med 2004, 256:1-1442. BeLcher G, Lambert C, Goh KL, et aL. CardiovascuLar effects of treatment of type

42. diabetes with piogLitazone, metformin and gLicLazide. Int J CLin Pract, 2004, 58: 833- 837.